We are monitoring the impact of COVID-19 on Europe Ulcerative Colitis Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 6221
Share on
Share on

Europe Ulcerative Colitis Market Research Report - Segmented By Product, By Type, By Route Of Administration & By Country(UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - Industry Analysis, Size, Share, Growth, Trends, & Forecasts 2019-2024

Pulished: February, 2020
ID: 6221
Pages: 145

Europe Ulcerative Colitis Market Size & Growth (2019 - 2024)

As per the research report, the size of the Europe Ulcerative Colitis Market is valued at USD 1.39 billion in 2019 and is projected to grow at a CAGR of 6.1%, to reach USD 1.86 billion by 2024 during the forecast period 2019-2024.

Ulcerative Colitis is an inflammatory bowel disease that results in ulcers and inflammation of the rectum and colon. The disease usually lasts long term and the symptoms include diarrhea with blood and abdominal pain. It can also result in inflammations in several body parts and can also lead to colon cancer.

The number of patients suffering from ulcerative colitis is increasing from the past few years which is certainly a major factor driving the demand of the market. Increasing stress levels among individuals and the adoption of an unhealthy diet are also some of the common factors for the growth of the ulcerative colitis market in Europe. Awareness over the symptoms of the disease in the early stage is also propelling the demand of the market as an early diagnosis of any disease may have a permanent cure. Increasing support from the government and non-government agencies is also accelerating the demand for the ulcerative colitis market in Europe.

However, high cost for treatment procedure as the procedure may also involve surgery if the condition of the patient is severe which is impeding the growth rate of the market. Fluctuations in the availability of raw materials and high manufacturing costs are also slowly limiting the demand for the ulcerative colitis market in Europe. Lack of standardization may also impact negatively on the growth rate of the market. The challenging factor for the market lies in the lack of awareness of the availability of certain treatment procedures in undeveloped countries.

Growing investments in research centers by both private and public organizations is anticipated to present growth opportunities for the market. Rise in the disposable income in urban areas is also likely to outshine the demand of the ulcerative colitis market in Europe. Launch of government schemes in favor of the common people and also focus on improving services in healthcare centers are greatly influencing the demand of the market tremendously. The emergence of the latest technologies in the medical sector is enhancing the growth rate of the Europe ulcerative colitis market.

This research report segmented and sub-segmented into the following categories:

  • By Product: Monoclonal Antibodies, Biosimilars, And Pharmaceuticals
  • By Type: Proctosigmoiditis, Ulcerative Proctitis, Pancolitis, And Left-Sided Colitis
  • By Route Of Administration: Oral And Injectable
  • By Country: UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe

Proctosigmoiditis is the most common type of ulcerative colitis and hence it holds the major market share.

In Europe, the market is growing at a faster rate from recent years by owing to the rise in the number of patients flow to the hospitals with ulcerative colitis. Creating awareness among people so that they can reduce the severity of the disease when it is diagnosed at the early stages is fuelling the demand of the market in this region. Also, increasing healthcare centers with good infrastructure in developed and developing countries is ascribed to bolster the growth rate of the ulcerative colitis market. Europe is having a constant economic growth from the past few years which is straightly magnifying the growth rate of the market. Furthermore, the prevalence of quality treatment procedures at any cost is also gearing up the demand of the market in Europe.

Key players operating in the Europe Ulcerative Colitis Market profiled in this report are Abbott Laboratories, GlaxoSmithKline, Pfizer, Takeda Pharmaceuticals, AbbVie, Johnson and Johnson, Merck, Sanofi, F. Hoffmann-La Roche and Shire Pharmaceuticals.

1. Introduction       

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods

                1.4 General Study Assumptions                                

2. Research Methodology                 

                2.1 Introduction     

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                           

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                      

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline

3. Overview             

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 Epidemology    

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)          

                4.1 Market Drivers

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market    

5. Market Segmentation                    

                5.1 Product                                        

                                5.1.1 Introduction                           

                                5.1.2 Monoclonal Antibodies                     

      5.1.2.1 Humira  

      5.1.2.2 Simponi                

      5.1.2.3 Remicade             

      5.1.2.4 Entyvio  

                                5.1.3 Biosimilars                               

                                5.1.4 Pharmaceuticals                   

      5.1.4.1 Mesalamine        

                      5.1.4.1.1 Asacol HD

                      5.1.4.1.2 Pentasa

                      5.1.4.1.3 Lialda

                      5.1.4.1.4 sfRowasa

      5.1.4.2 Balsazide              

                      5.1.4.2.1 Colazal

                      5.1.4.2.2 Giazo

      5.1.4.3 Budesonide        

                                5.1.5  Y-o-Y Growth Analysis, By Product                              

                                5.1.6  Market Attractiveness Analysis, By Product                            

                                5.1.7  Market Share Analysis, By Product                              

                5.2 Type    

                                5.2.1 Introduction                           

                                5.2.2 Proctosigmoiditis                  

                                5.2.3 Ulcerative Proctitis                              

                                5.2.4 Pancolitis                 

                                5.2.5 Left-sided Colitis                   

                                5.2.5 Y-o-Y Growth Analysis, By Type                     

                                5.2.6 Market Attractiveness Analysis, By Type                   

                                5.2.7 Market Share Analysis, By Type                     

                5.3 Route of Administration                                       

                                5.3.1 Introduction                           

                                5.3.2 Oral                            

                                5.3.3 Injectable                

                                5.3.4 Y-o-Y Growth Analysis, By Route of Administration                               

                                5.3.5  Market Attractiveness Analysis, By Route of Administration                            

                                5.3.6  Market Share Analysis, By Route of Administration                             

6. Geographical Analysis                    

                6.1 Introduction     

                                6.1.1 Regional Trends                    

                                6.1.2 Impact Analysis                     

                                6.1.3 Y-o-Y Growth Analysis                        

      6.1.3.1 By Geographical Area     

      6.1.3.2 By Product           

      6.1.3.3 By Type 

      6.1.3.4 By Route of Administration          

                                6.1.4  Market Attractiveness Analysis                     

      6.1.4.1 By Geographical Area     

      6.1.4.2 By Product           

      6.1.4.3 By Type 

      6.1.4.4 By Route of Administration          

                                6.1.5  Market Share Analysis                      

      6.1.5.1 By Geographical Area     

      6.1.5.2 By Product           

      6.1.5.3 By Type 

      6.1.5.4 By Route of Administration          

                6.2 U.K                                 

                6.3 Spain   

                6.4 Germany                                     

                6.5 Italy     

                6.6 France

7. Strategic Analysis             

                7.1 PESTLE analysis                                         

                                7.1.1 Political                     

                                7.1.2 Economic                 

                                7.1.3 Social                         

                                7.1.4 Technological                         

                                7.1.5 Legal                          

                                7.1.6 Environmental                       

                7.2 Porter’s Five analysis    

                                7.2.1 Bargaining Power of Suppliers                        

                                7.2.2 Bargaining Power of Consumers                    

                                7.2.3 Threat of New Entrants                     

                                7.2.4 Threat of Substitute Products and Services                              

                                7.2.5 Competitive Rivalry within the Industry                     

8. Market Leaders' Analysis              

                8.1 Abbott Laboratories     

                                8.1.1 Overview                 

                                8.1.2 Product Analysis                   

                                8.1.3 Financial analysis                  

                                8.1.4 Recent Developments                       

                                8.1.5 SWOT analysis                       

                                8.1.6 Analyst View                          

                8.2 GlaxoSmithKline                                       

                8.3 Pfizer  

                8.4 Takeda Pharmaceuticals                                       

                8.5 AbbVie                                         

                8.6 Johnson and Johnson  

                8.7 Merck 

                8.8 Sanofi 

                8.9 F. Hoffmann-La Roche 

                8.10 Shire Pharmaceuticals                                         

9. Competitive Landscape                 

                9.1 Market share analysis  

                9.2 Merger and Acquisition Analysis                                       

                9.3 Agreements, collaborations and Joint Ventures                                         

                9.4 New Product Launches                                         

10. Market Outlook and Investment Opportunities               

Appendix                 

                a) List of Tables                                

                b) List of Figures    

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms By Route Of Administration with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Ulcerative Colitis Market By Product, From 2019-2024( USD Billion )
  2. Europe Monoclonal Antibodies Market By Region, From 2019-2024( USD Billion )
  3. Europe Biosimilars Market By Region, From 2019-2024( USD Billion )
  4. Europe Pharmaceuticals Market By Region, From 2019-2024( USD Billion )
  5. Europe Ulcerative Colitis Market By Type, From 2019-2024( USD Billion )
  6. Europe Proctosigmoiditis Market By Region, From 2019-2024( USD Billion )
  7. Europe Ulcerative Proctitis Market By Region, From 2019-2024( USD Billion )
  8. Europe Pancolitis Market By Region, From 2019-2024( USD Billion )
  9. Europe Left sided Colitis Market By Region, From 2019-2024( USD Billion )
  10. Europe Ulcerative Colitis Market By Route of Administration, From 2019-2024( USD Billion )
  11. Europe Oral Market By Region, From 2019-2024( USD Billion )
  12. Europe Injectable Market By Region, From 2019-2024( USD Billion )
  13. U.K. Ulcerative Colitis Market By Product, From 2019-2024( USD Billion )
  14. U.K. Ulcerative Colitis Market By Type, From 2019-2024( USD Billion )
  15. U.K. Ulcerative Colitis Market By Route of Administration, From 2019-2024( USD Billion )
  16. Germany Ulcerative Colitis Market By Product, From 2019-2024( USD Billion )
  17. Germany Ulcerative Colitis Market By Type, From 2019-2024( USD Billion )
  18. Germany Ulcerative Colitis Market By Route of Administration, From 2019-2024( USD Billion )
  19. France Ulcerative Colitis Market By Product, From 2019-2024( USD Billion )
  20. France Ulcerative Colitis Market By Type, From 2019-2024( USD Billion )
  21. France Ulcerative Colitis Market By Route of Administration, From 2019-2024( USD Billion )
  22. Italy Ulcerative Colitis Market By Product, From 2019-2024( USD Billion )
  23. Italy Ulcerative Colitis Market By Type, From 2019-2024( USD Billion )
  24. Italy Ulcerative Colitis Market By Route of Administration, From 2019-2024( USD Billion )
  25. Spain Ulcerative Colitis Market By Product, From 2019-2024( USD Billion )
  26. Spain Ulcerative Colitis Market By Type, From 2019-2024( USD Billion )
  27. Spain Ulcerative Colitis Market By Route of Administration, From 2019-2024( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample